- IDEAYA Biosciences (NASDAQ:IDYA) announced dose expansion of the ongoing Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma ("MUM").
- The company expects to enroll ~40 patients for the IDE196 and binimetinib combination arm in the trial conducted in collaboration with Pfizer (NYSE:PFE).
- The decision on dose-expansion was based on early clinical activity, including the proportion of patients with tumor reduction, IDEAYA said.
- The interim data from the IDE196 and binimetinib clinical combination arm in MUM and the IDE196 monotherapy arm of the Phase 1/2 basket trial in MUM are likely in 2021 along with results on GNAQ/11-mutation skin melanoma.
- In September, IDEAYA announced the expansion of the collaboration and supply agreement with Pfizer for the evaluation of a combination study of IDE196 in patients with solid tumors.